Company
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.
Zoryve Cream 0.3% Approved by FDA for Pediatric Plaque Psoriasis Starting at Age 2
Plaque psoriasis treatment options for young children have expanded significantly following a major regulatory update in the United States. The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Zoryve cream 0.3%, allowing its use in children as young as 2 years old for the treatment of Plaque Psoriasis, including sensitive and intertriginous areas of the body.
This update marks an important milestone in pediatric dermatology, particularly for families managing long-term inflammatory skin disease in very young children. The approval was announced by Arcutis Biotherapeutics following supportive clinical trial data demonstrating safety, tolerability, and efficacy in younger pediatric populations.
The expanded approval of Zoryve cream 0.3% now includes children aged 2 years and older. Previously, the treatment was approved only for older pediatric patients and adults. With this decision, it becomes one of the first once-daily, non-steroidal topical therapies available for very young children with plaque psoriasis.
According to the FDA update, the approval is supported by clinical studies evaluating pharmacokinetics, safety outcomes, and early signs of efficacy in children aged 2 to 5 years. These studies included both short-term controlled exposure research and longer-term extension data to better understand continued use in a pediatric population.
The company stated that this approval represents the seventh FDA approval for the Zoryve product line in four years, highlighting the rapid expansion of its dermatology portfolio.
Zoryve is a topical formulation of roflumilast, which is a phosphodiesterase-4 (PDE4) inhibitor. PDE4 is an enzyme involved in inflammatory pathways in the skin. By inhibiting this enzyme, Zoryve helps reduce the production of inflammatory mediators that contribute to redness, scaling, itching, and plaque formation.
Unlike topical corticosteroids, Zoryve is steroid-free and can be used on different areas of the body without strict duration limits. This is especially relevant for children who may require long-term management of chronic skin disease in sensitive regions such as the face, groin, and skin folds.
The FDA expansion was primarily supported by a 4-week maximal usage systemic exposure study and a longer open-label extension trial. These studies examined children aged 2 to 5 years who had measurable body surface involvement of plaque psoriasis.
Key findings from the research program included:
The results were generally aligned with earlier Phase 3 trials conducted in adolescents and adults, suggesting that the therapeutic response remains consistent across age groups.
Researchers also evaluated long-term safety data over periods extending up to 24 weeks, helping to assess the suitability of continuous use in a chronic condition like plaque psoriasis.
Plaque psoriasis in children is often underrecognized and difficult to manage due to limited treatment options. Traditional therapies such as topical steroids can be effective but are not always suitable for long-term use, especially on delicate or highly sensitive skin areas.
Medical experts note several challenges in pediatric psoriasis care:
According to dermatology specialists involved in clinical research, having a non-steroidal option that can be used continuously provides a meaningful advancement in care. It allows clinicians more flexibility in treatment planning and reduces reliance on intermittent steroid cycles.
The active ingredient in Zoryve, roflumilast, works by targeting inflammatory signaling pathways in the skin. By inhibiting PDE4, it helps regulate immune system activity locally without systemic immunosuppression at therapeutic topical doses.
Potential benefits of this mechanism include:
Because plaque psoriasis is a chronic immune-mediated disease, therapies that can be used continuously without major restrictions are particularly valuable in long-term disease control strategies.
Arcutis Biotherapeutics has also emphasized patient access initiatives alongside the approval. These programs are designed to improve affordability and treatment continuity.
Key support services include:
These services are intended to reduce barriers to treatment, particularly for chronic conditions that require long-term adherence.
The expansion of Zoryve to younger children reflects a broader trend in dermatology toward targeted, non-steroidal therapies. Over the past several years, PDE4 inhibition has emerged as an important approach in inflammatory skin disease management.
For clinicians, this approval expands the therapeutic toolkit available for managing pediatric plaque psoriasis, particularly in cases where steroid-sparing strategies are preferred.
It also reflects growing interest in developing treatments that are safe for early childhood use, a population historically underserved in dermatologic drug development.
As with all prescription therapies, Zoryve cream includes important safety considerations. Reported side effects in clinical studies included mild gastrointestinal symptoms, headache, and upper respiratory infections. The medication is contraindicated in patients with moderate to severe liver impairment.
The foam formulation also includes flammable propellants, requiring avoidance of heat, flame, or smoking during and immediately after use.
Patients and caregivers are advised to follow prescribing instructions carefully and consult healthcare professionals for personalized guidance.
The FDA expansion of Zoryve for use in children as young as 2 years old represents a significant development in the treatment of Plaque Psoriasis. Supported by clinical trial data and real-world safety evaluation, this approval provides a new non-steroidal option for families and clinicians managing a challenging chronic condition in young patients.
With continued innovation from Arcutis Biotherapeutics and regulatory oversight from the FDA, pediatric dermatology treatment options are gradually expanding toward safer, more flexible long-term therapies.
Source: Arcutis Biotherapeutics, Inc.
Disclaimer: This article is for informational purposes only. It is not medical advice, diagnosis, or treatment guidance. Always consult a qualified healthcare professional before starting or changing any medical treatment.